Niche oncology Target cancer-focused offering with a unique protein-specific approach for colon cancer, presenting a clear value proposition for oncology departments and specialty pharma partners seeking differentiated therapies.

Virology potential Interest from teams exploring novel virology applications could expand partnerships beyond oncology, opening opportunities with research collaborations or licensing deals around viral targets or antiviral platforms.

Small-company agility High potential for rapid decision cycles and flexible collaboration terms given the small team size, enabling pilots, early access programs, or co-development arrangements with larger pharma customers.

Financial foothold Current revenue and modest funding level signal opportunities to propose staged investments, milestone-based deals, or grant-supported partnerships to accelerate development and clinical milestones.

Digital maturity Adopted cloud and analytics tooling enables data-driven outreach, targeted campaigns, and scalable due diligence for potential partners; leverage digital channels to identify and engage interested collaborators.